Latest Breaking News On - Euronext growth stock exchange - Page 3 : vimarsana.com

PHARNEXT: Pharnext unveils new calendar for negotiations valuing its drug candidate in Charcot-Marie-Tooth disease type 1A

PHARNEXT: Pharnext announces being at D-18 before publication of topline results from pivotal Phase III clinical trial (PREMIER trial) in Charcot-Marie-Tooth disease type 1A

Pharnext Sa : Pharnext announces being at D-18 before publication of topline results from pivotal Phase III clinical trial (PREMIER trial) in Charcot-Marie-Tooth disease type 1A -November 23, 2023 at 02:35 am EST

PARIS, France, November 23, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high.

Pharnext Sa : Pharnext receives a new offer valuing its drug candidate for Charcot-Marie-Tooth disease type 1A at more than EUR500m and the support of its financial partners -October 30, 2023 at 03:40 am EDT

PARIS, France, October 30, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high.

Pharnext Sa : Pharnext updates on the development program in China for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) -September 28, 2023 at 02:35 am EDT

PARIS, France, 28 September 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high.